Ozmosi | BLS-ILB-E710C Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

BLS-ILB-E710C

Alternative Names: bls-ilb-e710c, bls ilb e710c, bls ilb-e710c
Clinical Status: Inactive
Latest Update: 2020-02-07
Latest Update Note: Clinical Trial Update

Product Description

BLS-ILB-E710C is being developed by BioLeaders for the treatment of patients with Cervical Intraepithelial Neoplasia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02195089?term=BLS-ILB-E710C&draw=2&rank=2)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioLeaders
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Cervical Cancer|Carcinoma in Situ|Cervical Intraepithelial Neoplasia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03274206

BLS-ILB-E710c-202

P2

Unknown status

Cervical Cancer|Carcinoma in Situ|Cervical Intraepithelial Neoplasia

2020-08-01

12%

2022-02-02

Recent News Events

Date

Type

Title